U.S. Biotech Stock News

In recent days, Robinhood Markets has been in focus as analysts highlight its rapid rollout of products like AI assistant Cortex, prediction markets, and expanded crypto tools, alongside upcoming fourth-quarter 2025 results and leadership changes including a new CFO and its chief legal officer joining FINRA's Board. At the same time, Robinhood's growing exposure to cryptocurrencies, tokenization themes, and international crypto-brokerage acquisitions is tying its business prospects more...

Alnylam Pharmaceuticals (ALNY) is in focus as management prepares to outline a new five year plan at the 44th Annual J.P. Morgan Healthcare Conference, along with preliminary 2025 revenue updates and a 2026 outlook. See our latest analysis for Alnylam Pharmaceuticals. At a share price of $422.5, recent trading has been choppy, with a 1-day share price return of 3.96% and 7-day share price return of 6.25%, set against a 90-day share price return of 7.54%. The 1-year total shareholder return of...

Newmont has recently drawn attention as gold prices climbed and investors sought safe-haven exposure, supported by its strong free cash flow and position as the only gold producer in the S&P 500. The company’s visibility has been amplified by analyst commentary, including Jim Cramer’s praise and expectations for higher earnings, alongside a leadership transition and an upcoming earnings report that could further influence sentiment. We’ll now examine how rising gold prices and safe-haven...

Analyst firm Needham & Company has taken a more optimistic view on Amkor Technology (AMKR), pointing to its position in advanced semiconductor packaging for AI chips and the potential for outsourced work from Taiwan Semiconductor Manufacturing Co. See our latest analysis for Amkor Technology. The recent enthusiasm around Amkor, including its 25 year high tied to AI packaging expectations, aligns with strong momentum, with a 90 day share price return of 72.12% and a 1 year total shareholder...

Sarepta Therapeutics has submitted a clinical trial application to New Zealand’s Medsafe for INSIGHTT, a first-in-human study of SRP-1005, its investigational siRNA therapy for Huntington’s disease, aiming to begin dosing in the second quarter of 2026. This move extends Sarepta’s next-generation siRNA platform into a high unmet-need neurodegenerative condition, adding to a pipeline that already spans multiple muscular and central nervous system disorders. Next, we’ll examine how launching...

Why Affirm is suddenly in the spotlight Affirm Holdings (AFRM) is back in focus as investors weigh upbeat commentary from TV personality Jim Cramer and bullish options trades against fresh warnings about consumer credit stress and rising default risks. See our latest analysis for Affirm Holdings. At a share price of $83.05, Affirm’s recent moves have been tied to this tug-of-war between upbeat commentary, bullish long-dated call options, and concerns about consumer credit health, with a...

If you are wondering whether HCI Group's current share price lines up with its underlying value, you are not alone. This article is built to help you make sense of that question step by step. HCI Group's share price closed at US$173.71, with a 1 year return of 53.3% and a 3 year return that is very large, while the stock has seen a 9.4% decline over the last 7 days and a 5.5% decline year to date. These recent moves sit alongside HCI Group's longer term share price record, including a 30 day...

Event driven snapshot of AMETEK AMETEK (AME) has come onto investors’ radar without a clear single news catalyst, which puts the focus squarely on its recent share performance and current valuation for anyone tracking industrial and electronics names. See our latest analysis for AMETEK. AME’s share price has tracked higher in recent months, with a 30 day share price return of 5.98% and a 90 day share price return of 15.20%. This has contributed to a 1 year total shareholder return of 19.14%...

BWS Financial’s decision to name Innodata (INOD) a Top Pick, together with its focus on a new government contract and momentum in AI data services, has put fresh attention on the stock’s investment case. See our latest analysis for Innodata. The upgrade and government contract news arrives after a volatile stretch, with a 7 day share price return of 25.67% and a 90 day share price decline of 30.20%. At the same time, the 1 year total shareholder return of 74.18% and the very large 3 year and...

If you are wondering whether Circle Internet Group at around US$80.59 is a bargain or just expensive hype, you are not alone. That is exactly what this article is going to unpack. The share price has been fairly active recently, with a 1.6% return over the last 7 days, a 4.0% decline over the last 30 days, and a 3.5% decline year to date. This raises questions about how the market is reassessing its potential and risk. Recent coverage around Circle has focused on its role in the USDC...

Recent 13F filings showing multiple prominent investors adding to Elevance Health (ELV) have put the stock on many radar screens, as buyers point to the company’s scale, cost discipline, and steady capital returns. See our latest analysis for Elevance Health. That interest from large investors comes as Elevance Health’s share price has climbed 10.91% over the past month and 3.51% year to date, even though the 1 year total shareholder return is slightly negative at 2.47%. This suggests recent...

If you are wondering whether Vistra's current share price offers good value or is starting to look stretched, you are not alone. The stock recently closed at US$154.60, after a 4.2% decline over the last week, a 6.9% decline over the last month, and a 6.4% decline year to date, even though the 3 year return is very large and the 5 year return is close to 7x. These return figures have kept Vistra on many investors' watchlists, as the long run share price history sets a very different tone...

If you are wondering whether Kodiak Sciences' share price still reflects its true worth after a strong run, this article walks through what the current valuation might be telling you. The stock closed at US$27.07, with returns of 3.6% over 30 days, 4.0% year to date and 194.2% over the last year, alongside a 3.2% decline over the past week and a 236.7% gain across three years, compared with an 82.4% decline over five years. Recent coverage around Kodiak Sciences has centered on its position...

If you are wondering whether Ternium’s share price still lines up with its underlying value, you are not alone. This article focuses on what the current market price might be implying. Ternium’s stock last closed at US$40.67, with returns of 6.5% over 7 days, 9.1% over 30 days, 3.9% year to date, 53.4% over 1 year and 88.4% over 5 years. This naturally raises questions about how much value is already reflected in the price. Recent attention on Ternium has centered on how it fits into the...

If you are wondering whether Huntington Bancshares' current share price still offers value, you are not alone. This article walks through what the numbers say about that question. With the stock at US$18.14 and returns of 4.6% over 7 days, 7.1% over 30 days, 3.8% year to date, 14.7% over 1 year, 42.8% over 3 years and 52.3% over 5 years, many investors are asking what is already priced in. Recent headlines around Huntington Bancshares have focused on the broader US regional banking sector,...

Braze recently reported a past-quarter revenue increase of 25.5% year on year, beating analyst expectations for both revenue and EBITDA, underscoring strong demand for its customer engagement platform. The company’s technology now powers interactions with 6.2 billion monthly active users, highlighting its extensive reach in personalized, cross-channel customer engagement for global brands. Next, we’ll examine how Braze’s revenue outperformance and operational strength influence its existing...

Taysha Gene Therapies (TSHA) drew fresh attention after dosing the first patient in its REVEAL pivotal trial for TSHA-102 in Rett syndrome and securing FDA alignment on safety data for its planned BLA submission. See our latest analysis for Taysha Gene Therapies. Against this backdrop, Taysha Gene Therapies’ share price sits at US$5.31, with a 90 day share price return of 6.2% and a 1 year total shareholder return above 170%. This indicates that momentum has been building despite some recent...

In early January 2026, Medtronic reported real-world data in Diabetes Care showing its MiniMed 780G insulin pump helped users reach American Diabetes Association time-in-range goals even on days when mealtime boluses were missed, while an analyst at William Blair upgraded the stock to Outperform citing momentum across several new product launches. The Diabetes Care analysis is especially important because it suggests optimized MiniMed 780G settings may meaningfully ease the day-to-day burden...

If you are wondering whether Interactive Brokers Group's current share price offers good value or not, it helps to line up the recent performance with what the fundamentals might be pointing to. The stock last closed at US$71.34, with returns of 10.9% over 7 days, 8.4% over 30 days, 6.1% year to date, 50.3% over 1 year and 288.7% over 3 years. These figures can change how investors think about both growth potential and risk. Recent coverage has focused on Interactive Brokers Group's position...

Marzetti (MZTI) is in focus after reporting quarterly results that topped revenue expectations, with record sales, gross profit, and operating income drawing renewed attention to its mix of branded products and licensed sauces. See our latest analysis for Marzetti. At a share price of $165.06, Marzetti’s recent 4.07% 1 month share price return sits against a 1 year total shareholder return of 0.58% decline and a 5 year total shareholder return of 5.86%, suggesting modest long term gains with...

If you are looking at Banc of California and wondering whether the current share price gives you good value, this article will walk through what the numbers actually say. The stock recently closed at US$20.11, with returns of 4.3% over the past week, 5.0% over the past month, 3.4% year to date and 32.8% over the last year. Recent news around Banc of California has focused on ongoing integration of its expanded banking platform and how investors are reacting to changes in the regional banking...

If you are wondering whether Shopify's current share price still makes sense after its long run, you are not alone. The key question now is what that price actually implies about value. At a last close of US$166.74, Shopify's stock has returns of 3.6% over 7 days, 5.3% over 30 days, 6.1% year to date, 54.9% over 1 year and a very large gain over 3 years, with 5 year returns of 39.0%. Recent attention on Shopify has largely focused on its position as a leading ecommerce platform provider and...

CRISPR Therapeutics announced that its senior management team would present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, with the presentation webcast live and archived on the company’s website. This conference appearance offers investors a rare, concentrated window into how CRISPR Therapeutics frames the progress of its gene-editing pipeline and collaborations within its broader business story. We’ll now examine how this upcoming J.P. Morgan Healthcare...

If you are wondering whether Himax Technologies is reasonably priced or offering hidden value, you are not alone. This article focuses squarely on what the current share price might mean for long term investors. Himax shares last closed at US$8.28, with returns of 1.1% over 7 days, a 10.9% decline over 30 days, a 2.9% decline year to date, and gains of 9.4% over 1 year, 33.1% over 3 years, and 32.5% over 5 years that some investors may see as changing the balance between growth potential and...